Search Videos by Topic or Participant
Browse by Series:

Everolimus for pNETs and Carcinoid Tumors

Insights From: Matthews H. Kulke, MD, Harvard Medical School; Jonathan R. Strosberg, MD, Moffitt Cancer Center; James C. Yao, MD, University of Texas MD Anderson Cancer Center
Published: Monday, Dec 28, 2015


Everolimus, an mTOR inhibitor, and sunitinib, an antiangiogenic tyrosine kinase inhibitor, have been shown to extend time to progression in patients with metastatic pancreatic neuroendocrine tumors (pNETs). These agents are typically used in individuals who have progressed while on somatostatin analogs, states Jonathan R. Strosberg, MD, which are the first-line treatment of choice for most well differentiated tumors that are not too clinically aggressive.

Aphthous stomatitis is the most common toxicity with everolimus, and can be managed with steroid paste or mouthwash. Everolimus may also cause pneumonitis, which can range from mild inflammation and cough to significant cough and dyspnea. Dose reductions or treatment breaks may be appropriate strategies in more severe situations. The typical starting dose of everolimus is 10 mg daily, while dose reductions to 7.5 mg or 5 mg daily can occur, comments Strosberg.

Response to treatment can be assessed in various ways, such as radiographically through scans, biochemically with tumor markers, or clinically, using symptom improvement. Treatment with everolimus is often continued until evidence of disease progression, as there is no concern of cumulative toxicity, explains James C. Yao, MD. Yao’s practice repeats anatomic CT or MRI scans every 3 months to verify whether current treatment is still effective.

Recent data from the RADIANT-4 study showed that patients with advanced carcinoid tumors in the gastrointestinal tract or lung benefited from treatment with everolimus compared with placebo, with a significant improvement in progression-free survival, explains Matthew H. Kulke, MD. This suggests that everolimus may be effective in treating not only pNETs but other types of NETs as well, he adds.
Slider Left
Slider Right


Everolimus, an mTOR inhibitor, and sunitinib, an antiangiogenic tyrosine kinase inhibitor, have been shown to extend time to progression in patients with metastatic pancreatic neuroendocrine tumors (pNETs). These agents are typically used in individuals who have progressed while on somatostatin analogs, states Jonathan R. Strosberg, MD, which are the first-line treatment of choice for most well differentiated tumors that are not too clinically aggressive.

Aphthous stomatitis is the most common toxicity with everolimus, and can be managed with steroid paste or mouthwash. Everolimus may also cause pneumonitis, which can range from mild inflammation and cough to significant cough and dyspnea. Dose reductions or treatment breaks may be appropriate strategies in more severe situations. The typical starting dose of everolimus is 10 mg daily, while dose reductions to 7.5 mg or 5 mg daily can occur, comments Strosberg.

Response to treatment can be assessed in various ways, such as radiographically through scans, biochemically with tumor markers, or clinically, using symptom improvement. Treatment with everolimus is often continued until evidence of disease progression, as there is no concern of cumulative toxicity, explains James C. Yao, MD. Yao’s practice repeats anatomic CT or MRI scans every 3 months to verify whether current treatment is still effective.

Recent data from the RADIANT-4 study showed that patients with advanced carcinoid tumors in the gastrointestinal tract or lung benefited from treatment with everolimus compared with placebo, with a significant improvement in progression-free survival, explains Matthew H. Kulke, MD. This suggests that everolimus may be effective in treating not only pNETs but other types of NETs as well, he adds.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x